Please assess the completion status of the following clinical trial:

Trial Title: First in Human Study of ALS-002158; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has provided written consent.~* Subject is in good health as deemed by the investigator~* Creatinine clearance of greater than 50 mL/min (Cockcroft- Gault).~* Male or female, 18-55 years of age for HV and 18-65 years of age for subjects with CHC.~* Body mass index (BMI) 18-32 kg/m2 inclusive for HV and 18-36 kg/m2 for subjects with CHC, minimum weight 50 kg in both populations.~* A female is eligible to participate in this study if she is of non-childbearing potential.~* If male, subject is surgically sterile or practicing specific forms of birth control.~Additional inclusion criteria for subjects with CHC genotype 1 infection:~* Positive HCV antibody and a positive HCV RNA at screening.~* Documentation of CHC infection of greater than 6 months duration at screening.~* CHC genotype 1 infection at screening.~* HCV RNA viral load ≥ 105 and ≤ 108 IU/mL using a sensitive quantitative assay~* Liver biopsy within two years or Fibroscan evaluation within 6 months prior to screening that clearly excludes cirrhosis. Fibroscan liver stiffness score must be \< 12 kPa.~* Absence of hepatocellular carcinoma as indicated by an abdominal ultrasound scan during screening.~* No prior treatment for CHC.~* Absence of history of clinical hepatic decompensation.~* Laboratory values include:~  * prothrombin time \< 1.5 × ULN.~ * platelets \> 120,000/mm3.~ * albumin \> 3.5 g/dL, bilirubin \< 1.5 mg/dL at screening (subjects with documented Gilbert's disease allowed).~ * Serum ALT concentration \< 5 × ULN.~ * Alpha Fetoprotein (AFP) concentration ≤ ULN. If AFP is ≥ ULN, absence of a hepatic mass must be demonstrated by ultrasound within the screening period.~Exclusion Criteria:~* Clinically significant cardiovascular, respiratory, renal, gastrointestinal, hematologic, neurologic, thyroid, or any uncontrolled medical illness or psychiatric disorder.~* Positive test for HAV IgM, HBsAg, HCV Ab (HV only), or HIV Ab.~* Abnormal screening laboratory results that are considered clinically significant by the investigator.~* Clinically significant drug allergy such as, but not limited to, sulfonamides and penicillins, including those experienced in previous trials with experimental drugs.~* Participation in an investigational drug trial or having received an investigational vaccine within 30 days or 5 half lives (whichever is longer) prior to receiving study medication.~* Clinically significant blood loss or elective blood donation of significant volume.~* Laboratory abnormalities including:~  * Thyroid Stimulating Hormone (TSH) \>ULN.~ * Hematocrit \< 34 %.~ * White blood cell counts \< 3,500/mm3.~* For healthy volunteers, history of regular use of tobacco.~* The subject has a positive pre-study drug screen.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- ALS-002158 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy